• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Secondary amines

Recent Advances in the Study of 6-Methoxy-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine (CAS: 1260862-06-3)

The compound 6-Methoxy-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine (CAS: 1260862-06-3) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This heterocyclic scaffold is structurally related to several bioactive molecules, making it a promising candidate for drug discovery. Recent studies have focused on its synthesis, pharmacological properties, and mechanisms of action, particularly in the context of neurological and oncological disorders.

A 2023 study published in the Journal of Medicinal Chemistry explored the synthesis and optimization of 6-Methoxy-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine derivatives to enhance their blood-brain barrier permeability. The researchers employed a combination of computational modeling and in vitro assays to identify key structural modifications that improve bioavailability. Their findings suggest that specific substitutions at the pyrazine ring can significantly enhance the compound's pharmacokinetic profile without compromising its efficacy.

In another groundbreaking study, researchers investigated the compound's potential as an inhibitor of protein-protein interactions (PPIs) involved in cancer progression. Using high-throughput screening and X-ray crystallography, the team identified that 6-Methoxy-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine binds selectively to the p53-MDM2 interface, a critical target in oncology. This discovery opens new avenues for developing small-molecule therapeutics that can reactivate p53 in tumors with MDM2 amplification.

Furthermore, recent preclinical studies have highlighted the neuroprotective effects of this compound. A 2024 paper in ACS Chemical Neuroscience demonstrated that 6-Methoxy-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine exhibits potent antioxidant and anti-inflammatory properties in models of neurodegenerative diseases such as Alzheimer's and Parkinson's. The compound's ability to modulate glutamate receptors and reduce oxidative stress positions it as a potential multi-target therapeutic agent.

Despite these promising findings, challenges remain in translating these discoveries into clinical applications. Issues such as metabolic stability, off-target effects, and scalable synthesis need to be addressed. Ongoing research is focusing on prodrug strategies and formulation technologies to overcome these hurdles. Collaborative efforts between academia and industry are expected to accelerate the development of this compound into viable therapeutics.

In conclusion, 6-Methoxy-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine (CAS: 1260862-06-3) represents a versatile scaffold with broad therapeutic potential. Its applications span from oncology to neurology, driven by its unique pharmacological properties. Future research should prioritize structure-activity relationship studies and clinical validation to fully realize its potential in drug development.

• 90817-34-8(2-Methylamino-3-amino-6-methoxypyridine)
• 83732-76-7(Ethanol,2-[(3-amino-6-methoxy-2-pyridinyl)amino]-, hydrochloride (1:2))
• 1073633-84-7(1,4-dihydro-6-methoxy-Pyrido[2,3-b]pyrazin-3(2H)-one)
• 90817-35-9(Ethanol, 2-[(3-amino-6-methoxy-2-pyridinyl)amino]-)
• 83732-72-3(6-Methoxy-N2-methylpyridine-2,3-diamine dihydrochloride)
• 194720-55-3(6-Methoxy-N2-methylpyridine-2,3-diamine hydrochloride)
• 676609-30-6(Ethanol, 2-[(3-amino-6-methoxy-2-pyridinyl)methylamino]- (9CI))
• 677009-67-5(2-Propanol,1-[(3-amino-6-methoxy-2-pyridinyl)amino]-(9CI))
• 676609-36-2(1-Propanol,2-[(3-amino-6-methoxy-2-pyridinyl)amino]-(9CI))
• 951160-15-9(3,4-dihydro-6-methoxy-Pyrido[2,3-b]pyrazin-2(1H)-one)